CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

NEXT STORY
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
PREV STORY
Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PRA Health Sciences, Inc. Reports First Quarter 2021 Results

author_avatar
NASDAQ Market News

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

author_avatar
NASDAQ Market News

Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone

author_avatar
NASDAQ Market News